BridgeBio Pharma, Inc. recently announced a US$550,000,000 fixed-rate senior subordinated unsecured notes offering under Rule 144A, while updating investors on advancing late-stage programs and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results